Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
The HPV (human papillomavirus) vaccine prevents cancers caused by HPV, including cervical, throat, and anal cancers. HPV vaccines have been the subject of significant public debate, making transparent data access especially important.
The following symptoms are most frequently reported after vaccination:
Common:
Rare but reported:
HPV vaccination has higher reported rates of syncope (fainting) than most vaccines. This is likely because the vaccine is given to adolescents, who are more prone to vasovagal responses. The CDC recommends a 15-minute observation period after HPV vaccination. Many VAERS reports for HPV are fainting-related rather than indicating serious adverse effects.
HPV vaccination is routinely recommended starting at ages 11-12. See where it fits on the CDC vaccine schedule and our 2026 vaccine schedule analysis.
As of mid-2026, the HPV vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into HPV vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like HPV has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for HPV vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about HPV vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.
As of mid-2026, the HPV vaccine continues to be monitored through VAERS and complementary surveillance systems including the Vaccine Safety Datalink (VSD) and the Clinical Immunization Safety Assessment (CISA) project. No new safety signals have been identified in recent data that would change the established safety profile of this vaccine.
The HHS administration's announced development of AI-powered VAERS analysis tools may provide additional insights into HPV vaccine adverse event patterns. These tools aim to detect subtle signals that traditional statistical methods might miss, though their implementation timeline and methodology remain under development.
It's worth noting that VAERS reporting for routine vaccines like HPV has remained stable through the post-pandemic period. While COVID-19 vaccine reports surged and then declined, reporting patterns for established childhood and adult vaccines have been remarkably consistent, suggesting that the VAERS system continues to function as designed for ongoing safety surveillance.
When interpreting VAERS data for HPV vaccines, several key principles apply:
VAERS data is most useful as a starting point for conversation with your healthcare provider, not as a basis for medical decisions. If you're concerned about HPV vaccine side effects:
For the most up-to-date safety information, consult the CDC's vaccine information pages or speak with a qualified healthcare professional.